Emerging advances in the management of lung cancer.
Belani
Chandra P
CP
Department of Medicine, University of Pittsburgh School of Medicine, PA 15232, USA. belancip@msx.upmc.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives; D011099:Polyglutamic Acid / Q000627:therapeutic use / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D043823:Taxoids / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D043823:Taxoids; D011099:Polyglutamic Acid; D000069286:Bortezomib; D066246:ErbB Receptors; D017239:Paclitaxel; C509139:paclitaxel poliglumex